Anika Therapeutics financials
$19.95−3.55%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $32.6M | $29.6M | $30.6M | $27.8M | $28.2M | $26.2M | $30.6M | $29.6M | $30.7M | $29.0M | $43.0M | $41.5M |
| Gross profit | $21.2M | $19.0M | $19.2M | $15.6M | $14.4M | $14.7M | $17.1M | $19.4M | $20.5M | $19.0M | $26.3M | $24.9M |
| Gross margin | 65.1% | 64.2% | 62.6% | 56.0% | 50.9% | 56.1% | 56.0% | 65.7% | 66.7% | 65.4% | 61.3% | 60.2% |
| Operating income | $3.0M | -$5.5M | $646.0K | -$3.2M | -$4.2M | -$4.3M | -$705.0K | -$81.0K | -$1.8M | -$2.5M | -$63.8M | -$7.7M |
| Net income | $3.3M | -$5.1M | $292.0K | -$2.3M | -$4.0M | -$4.9M | -$21.9M | -$29.9M | -$88.0K | -$4.5M | -$63.0M | -$6.6M |
| Net margin | 10.1% | −17.1% | 1.0% | −8.4% | −14.1% | −18.6% | −71.4% | −101.2% | −0.3% | −15.6% | −146.6% | −15.9% |
| Diluted EPS | $0.24 | $-0.37 | $0.02 | $-0.16 | $-0.28 | $-0.34 | $-1.50 | $-2.03 | $0.00 | $-0.31 | $-4.30 | $-0.45 |
| EBITDA | $4.5M | -$4.1M | $2.0M | -$1.8M | -$2.8M | -$2.7M | $1.1M | $2.1M | $248.0K | -$442.0K | -$1.6M | -$4.1M |
| Operating cash flow | -$684.0K | -$4.8M | $4.6M | $6.9M | -$189.0K | -$130.0K | $1.6M | $5.0M | -$1.1M | -$126.0K | $3.6M | $6.5M |
| Free cash flow | -$2.1M | -$6.3M | $4.0M | $5.0M | -$1.7M | -$3.0M | $275.0K | $3.8M | -$4.5M | -$1.9M | $1.8M | $5.7M |
| Diluted shares | 13.7M | 13.5M | 14.1M | 14.4M | 14.5M | 14.3M | 14.6M | 14.8M | 14.9M | 14.7M | 14.6M | 14.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $38.4M | $41.0M | $57.5M | $58.0M | $53.2M | $53.4M |
| Short-term investments | $0.00 | $25.8M | $0.00 | $22.2M | $24.0M | $22.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $183.5M | $179.4M | $190.3M | $189.4M | $187.7M | $190.6M |
| Total liabilities | $46.2M | $45.5M | $46.8M | $42.6M | $40.0M | $42.2M |
| Shareholders' equity | $137.3M | $133.9M | $143.5M | $146.8M | $147.7M | $148.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology